$0.73
20.20% day before yesterday
Nasdaq, Dec 27, 10:17 pm CET
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Vaxart, Inc. Stock price

$0.73
+0.12 19.80% 1M
+0.06 9.73% 6M
+0.16 27.58% YTD
+0.13 21.80% 1Y
-5.96 89.08% 3Y
+0.39 116.53% 5Y
-23.47 96.98% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.12 20.20%
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Key metrics

Market capitalization $166.24m
Enterprise Value $130.61m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.79
P/S ratio (TTM) P/S ratio 9.92
P/B ratio (TTM) P/B ratio 2.43
Revenue growth (TTM) Revenue growth 303.27%
Revenue (TTM) Revenue $16.76m
EBIT (operating result TTM) EBIT $-71.70m
Free Cash Flow (TTM) Free Cash Flow $-51.35m
Cash position $58.71m
EPS (TTM) EPS $-0.41
P/E forward negative
P/S forward 4.85
EV/Sales forward 3.81
Short interest 5.00%
Show more

Is Vaxart, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Vaxart, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

Buy
100%

Financial data from Vaxart, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
17 17
303% 303%
100%
- Direct Costs 4.50 4.50
3% 3%
27%
12 12
5,938% 5,938%
73%
- Selling and Administrative Expenses 13 13
11% 11%
79%
- Research and Development Expense 66 66
10% 10%
395%
-67 -67
24% 24%
-401%
- Depreciation and Amortization 4.50 4.50
3% 3%
27%
EBIT (Operating Income) EBIT -72 -72
23% 23%
-428%
Net Profit -72 -72
19% 19%
-432%

In millions USD.

Don't miss a Thing! We will send you all news about Vaxart, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
26 days ago
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 2...
Neutral
Seeking Alpha
about 2 months ago
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer ...
Neutral
GlobeNewsWire
about 2 months ago
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
More Vaxart, Inc. News

Company Profile

Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Head office United States
CEO Steven Lo
Employees 125
Founded 2004
Website www.vaxart.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today